Olix Oil

OliX Pharmaceuticals is a clinical-stage biopharmaceutical company based in South Korea that specializes in the development of RNA interference (RNAi) therapeutics. The company utilizes its proprietary Cell-Penetrating Asymmetric siRNA (CP-asiRNA) platform to develop treatments for diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and liver diseases. Their lead program, OLX101A, is currently in Phase 2 clinical trials for the treatment of hypertrophic scarring. OliX's technology is designed to provide efficient gene silencing with improved cellular uptake and reduced off-target effects compared to traditional siRNA. The company is publicly traded on the KOSDAQ and has established strategic collaborations with global partners such as Théa Open Innovation and Hansoh Pharmaceutical.